System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Giuseppe Vergaro is an expert in Cardiology at Fondazione Toscana Gabriele Monasterio (Italy). As of October 2026, ScienceLeadR ranks Giuseppe Vergaro in the top 1% of experts worldwide for Proteostasis Deficiencies, Cardiomyopathies and Heart Failure. Giuseppe Vergaro has authored 362 publications, the most recent in 2026, and is an investigator in 5 clinical trials, 4 of them ongoing. SLR score: 1,307 (community average: 125). How the SLR is computed.

LeadR Profile

Giuseppe Vergaro Fondazione Toscana Gabriele Monasterio Italy
1 307 ScienceLeadR Reputation 1307

Unlock

Register Login
Network Map

Cardiology

Subspecialties: Internal Medicine - Biochemistry - Medical Imaging

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2009 - 2026
Source: PubMed

Fondazione Toscana Gabriele Monasterio

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 362

Citations

Citations: 6 429 1st author: 50 Last author: 47 Unique author: 0

Main journals

Int J Cardiol 43
Eur Heart J Suppl 38
Eur Heart J 32
Eur J Heart Fail 20
J Am Coll Cardiol 19

Best Journals

Eur Heart J 11
Circulation 3
Nat Rev Cardiol 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Role of autopsy in sudden deaths from undiagnosed cardiac amyloidosis: a systematic review with an illustrative autopsy case.
PMID 42702192 — bradycardia, signs and symptoms, amyloidosis, amyloid, autopsy		Leg Med (Tokyo)20260
Raising diagnoses or doubts? RAISE score for transthyretin cardiac amyloidosis identification in aortic stenosis.
PMID 42858809 — constriction, pathologic, aortic valve stenosis, prealbumin, cardiology, amyloidosis, diagnosis, transthyretin cardiac amyloidosis		Int J Cardiol20260
Estimating the prevalence of transthyretin cardiac amyloidosis in the general population.
PMID 42687766 — heart failure, prealbumin, amyloidosis, prevalence, transthyretin cardiac amyloidosis		Eur J Heart Fail20260
Fibrosis in Cardiac Amyloidosis: How Much, How Relevant?
PMID 42524802 — fibrosis, cardiology, amyloidosis		J Am Coll Cardiol20260
From diagnosis to quantification of amyloid burden: Reappraising the wall thickness-to-voltage ratio in cardiac amyloidosis.
PMID 42486370 — cardiology, amyloidosis, diagnosis, amyloid		Int J Cardiol20260

Clinical Studies 5

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 3
N/A 1
Phase 2 1

By status:

Active not recruiting 2
Not yet recruiting 1
Recruiting 1
Unknown 1

By type:

Interventional 4
Observational 1

By Monocentric/Multicentric:

monocentric 0
multicentric2to4 0
multicentric5to9 0
multicentricup10 5

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

4 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A study to determine if ALXN2220 is effective safe and tolerable in adults with Transthyretin Amyloid Cardiomyopathy (ATTR CM)
2023-506669-70-00 — safety, prealbumin, amyloid, cardiomyopathies, transthyretin amyloid cardiomyopathy, transthyretin amyloidosis		Phase 3Active not recruiting2024
TRITON CM A Study to Evaluate Nucresiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy
2024-519917-72-00 — safety, prealbumin, amyloidosis, therapeutics, cardiomyopathies, transthyretin amyloidosis		Phase 3Not yet recruiting2025
Study to Evaluate Safety Tolerability and Drug Levels of BMS 986435 MYK 224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
NCT06122779 — safety, heart failure, pharmaceutical preparations, heart, multiple chronic conditions, heart failure, diastolic, pharmacokinetics		Phase 2Active not recruiting2023
COLchicine and Non enteric Coated Aspirin in the Cardiovascular Outcomes Trial of Patients With Type 2 Diabetes
NCT05633810 — diabetes mellitus, heart diseases, colchicine, heart, cardiovascular diseases, tablets, aspirin, diabetes mellitus, type 2		Phase 3Recruiting2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS